HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: A combined analysis of TBCRC 006/023 and PAMELA trials; Abstract #509

Clinical Evaluation of Germline Polymorphisms (SNPs) Associated with Disease Response to Capecitabine in Metastatic Breast Cancer (MBC) (TBCRC 015); Abstract #1071

TBCRC 026 Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET) with pathological complete response (pCR) to pertuzumab and trastuzumab in patients with primary operable HER2-positive breast cancer; Abstract #511

A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies (TBCRC 044); Abstract #TPS1113